Treace Medical Concepts Announces Upcoming Financial Results
Treace Medical Concepts, Inc. (Nasdaq: TMCI), a leader in medical technology focusing on advanced surgical treatments for bunions and other midfoot deformities, is preparing to release its financial results for the third quarter of 2024. This announcement will occur after the market closes on November 5, 2024, with a conference call scheduled for 4:30 PM ET, where management will discuss the results in detail.
Event Details and Participation
Participants wishing to join the financial conference call are encouraged to register for the event. Once registered, they will receive unique dial-in numbers and a personal identification number (PIN) for access. In addition to the live call, a recorded version will be available on the company’s investor relations website for those unable to attend live.
Treace’s Innovations in Bunion Surgery
Focusing on bunion corrections, Treace Medical Concepts has developed revolutionary systems aimed at enhancing patient outcomes. The patented Lapiplasty® 3D Bunion Correction® System addresses toenail deformities by correcting the bunion in three planes, providing a comprehensive solution that directly tackles the root causes of bunion-related issues. This method allows patients to return to their daily activities much quicker, a significant advantage for those affected by this condition.
Addressing the Needs of Surgical Candidates
Approximately 67 million people in the United States suffer from bunions, with around 1.1 million projected surgical candidates annually, as per Treace's estimates. With this substantial patient base, Treace Medical Concepts continually seeks to improve surgical techniques and technologies, making a significant impact on the lives of many individuals.
Expanding Product Offerings
Beyond traditional bunion surgery, Treace has launched the Adductoplasty® Midfoot Correction System and the Hammertoe PEEK Fixation System. These products represent a firm commitment to comprehensive foot and ankle health and cater to various related deformities, thus expanding Treace's market presence.
Innovative Fixation Solutions
The company has also introduced the SpeedPlate™ Rapid Compression Implants, showcasing their dedication to innovation and versatility in surgical procedures. This comprehensive platform supports procedures related to both Lapiplasty® and Adductoplasty®, aiming for a seamless experience across various common foot fusion surgeries.
Staying Connected with Treace
Treace Medical Concepts encourages patients, healthcare professionals, and investors to engage with them through social media platforms like LinkedIn, X, Facebook, and Instagram, where they share updates about their products and any innovations in the pipeline. Connecting through these platforms allows individuals to stay informed about Treace's advancements, success stories, and opportunities for collaboration.
Contact Information for Inquiries
For queries regarding financial performance or product specifications, individuals can reach out directly. Mark L. Hair serves as the Chief Financial Officer of Treace Medical Concepts, and he is available at (904) 373-5940 or via email at mhair@treace.net.
For investor relations, Gilmartin Group’s Vivian Cervantes is available to assist and can be contacted through email at IR@treace.net.
Frequently Asked Questions
What is Treace Medical Concepts known for?
Treace Medical Concepts specializes in medical technologies focusing on surgical treatments for bunions and midfoot deformities.
When will Treace release its Q3 2024 financial results?
The financial results are set to be announced on November 5, 2024, after the market closes.
How can I participate in the financial conference call?
Interested participants can register online to receive their dial-in numbers and pin for the call scheduled for 4:30 PM ET on the announcement day.
What products does Treace offer?
Treace offers the Lapiplasty® 3D Bunion Correction® System and the Adductoplasty® Midfoot Correction System, among others focused on foot deformities.
Who can I contact for investor relations?
For investor inquiries, you can contact Vivian Cervantes at Gilmartin Group via email at IR@treace.net.
